Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyDevoted Health Liver Fibrosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentDevoted HealthPolicy UMGT.CL.0055

    Non-invasive Liver Fibrosis Testing

    Customize your policy alerts

    Sign up for devoted_health Policy UMGT.CL.0055 alerts

    Get alerted when Policy UMGT.CL.0055 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of non-invasive serologic and imaging tests used to assess hepatic fibrosis for members with chronic viral hepatitis or other chronic liver disease across all Devoted Health plans.

    Policy Summary
    PayerDevoted Health
    PolicyNon-invasive Liver Fibrosis Testing
    Policy CodePolicy UMGT.CL.0055
    Change TypeNo material change
    Effective DateApr 22, 2026
    Last ReviewApr 13, 2026
    Next Review DateApr 15, 2027
    Key ActionDocument a qualifying chronic liver disease or chronic viral hepatitis diagnosis, the testing indication, and compliance with the 6-month testing intervals.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All plansPolicy applicability
    6 moMinimum testing interval
    F2+Significant fibrosis
    5Covered testing methods
    3Non-covered categories
    Policy Summary
    PayerDevoted Health
    PolicyNon-invasive Liver Fibrosis Testing
    Policy CodePolicy UMGT.CL.0055
    Change TypeNo material change
    Effective DateApr 22, 2026
    Last ReviewApr 13, 2026
    Next Review DateApr 15, 2027
    Key ActionDocument a qualifying chronic liver disease or chronic viral hepatitis diagnosis, the testing indication, and compliance with the 6-month testing intervals.
    SourceLink
    On This Page
    Coverage CriteriaTesting IntervalsAuthorization and Documentation RequirementsClinical BackgroundFibrosis Staging and Testing Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Covered Indications and Tests

    Covered when the member has a qualifying clinical setting and the requested test is listed as covered.

    Covered testing

    • Qualifying indication

      • Initial evaluation of chronic liver disease: Testing is performed at the time of diagnosis of chronic viral hepatitis, such as hepatitis C or hepatitis B, or another chronic liver disease, such as alcoholic liver disease, nonalcoholic fatty liver disease, primary sclerosing cholangitis, primary biliary cirrhosis, or hereditary hemochromatosis, to determine the presence or likelihood of fibrosis.
      • Follow-up of untreated chronic HCV: Testing is performed during follow-up care for untreated chronic hepatitis C to monitor disease progression.
      • Follow-up of other ongoing chronic liver disease: Testing is performed during follow-up care for other untreated or ongoing chronic liver disease, including alcoholic liver disease, nonalcoholic fatty liver disease, primary sclerosing cholangitis, primary biliary cirrhosis, or hereditary hemochromatosis, to monitor disease progression.
    • Covered test

      • Serologic tests: APRI or FIB-4 index.
      • Imaging tests: Transient elastography, acoustic radiation force impulse techniques including 2D shear wave elastography or point shear wave elastography, or magnetic resonance elastography.

        Magnetic resonance elastography is covered only for nonalcoholic fatty liver disease.

    Testing Frequency and Biopsy Interval

    Testing is not medically necessary and will not be approved when either interval restriction is violated.

    Timing restrictions

    • Excessive testing frequency: Performance of any non-invasive liver fibrosis test more often than every 6 months is not medically necessary and will not be approved.Not more often than every 6 months
    • Recent liver biopsy: Performance of a non-invasive liver fibrosis test within 6 months of a liver biopsy is not medically necessary and will not be approved.At least 6 months after liver biopsy

    Not Covered Tests and Indications

    The following tests or indications are not covered.

    Non-covered testing

    • Enhanced Liver Fibrosis Test.
    • Other serologic testing: All serologic liver fibrosis testing not listed as covered.
    • MRE outside NAFLD: Magnetic resonance elastography in cases other than nonalcoholic fatty liver disease.

    Evidence of Chronic Liver Disease

    Testing requires evidence supporting the presence of chronic liver disease.

    Evidence of chronic liver disease: Liver fibrosis testing is appropriate only when there is radiographic or serologic evidence of chronic liver disease.

    Examples include right upper quadrant ultrasound, CT, or MRI showing fatty liver or nodular liver, or positive HFE gene testing for hereditary hemochromatosis.

    Enhanced Liver Fibrosis Test is not covered because the policy does not include this test among covered non-invasive liver fibrosis testing methods.

    Serologic liver fibrosis testing is not covered when the test is not specifically listed among the covered methods. Covered serologic methods are APRI and the FIB-4 index.

    Magnetic resonance elastography (MRE) is not covered when performed for a condition other than nonalcoholic fatty liver disease (NAFLD).

    Liver fibrosis testing is not appropriate without radiographic or serologic evidence of chronic liver disease. Supporting evidence may include right upper quadrant ultrasound, CT, or MRI showing fatty or nodular liver, or positive HFE gene testing for hereditary hemochromatosis.

    A non-invasive liver fibrosis test must not be performed more often than every 6 months. Testing performed at a shorter interval is not medically necessary and will not be approved.

    A non-invasive liver fibrosis test performed within 6 months after a liver biopsy is not medically necessary and will not be approved.

    Testing Intervals

    Interval Between Non-Invasive Liver Fibrosis Tests
    Required intervalNot more often than every 6 months
    Applies toAny non-invasive test of liver fibrosis
    Coverage consequenceTesting performed more often than every 6 months is not medically necessary and will not be approved
    Interval Between Non-Invasive Testing and Liver Biopsy
    Required intervalAt least 6 months after liver biopsy
    Restricted timingA non-invasive liver fibrosis test must not be performed within 6 months of a liver biopsy
    Coverage consequence

    Authorization and Documentation Requirements

    Documentation Required

    Document Qualifying Disease and Indication

    Document the qualifying chronic liver disease and the testing indication in the medical record. Coverage applies at diagnosis to determine the presence or likelihood of fibrosis, or during follow-up of untreated or ongoing disease to monitor progression.

    • Qualifying conditions include chronic HCV or HBV; alcoholic liver disease; non-alcoholic fatty liver disease (NAFLD); primary sclerosing cholangitis; primary biliary cirrhosis; or hereditary hemochromatosis.
    • Covered non-invasive tests include APRI, FIB-4 index, transient elastography, acoustic radiation force impulse techniques (including 2D shear wave and point shear wave elastography), and magnetic resonance elastography (MRE) when the coverage criteria are met.
    Denial Risk

    Avoid Excessive Testing or Recent Biopsy

    Do not request authorization for a non-invasive liver fibrosis test performed more often than every 6 months or within 6 months of a liver biopsy. These services are not medically necessary and will not be approved.

    Clinical Background

    Hepatic fibrosis develops in response to chronic liver injury from toxins, infections, or chronic liver diseases such as viral hepatitis and nonalcoholic fatty liver disease. Although liver biopsy is the diagnostic gold standard, it is invasive and subject to complications and sampling error; therefore, serologic and imaging-based non-invasive tests may be used to estimate fibrosis stage. The METAVIR scale ranges from F0, indicating no fibrosis, through F4, indicating cirrhosis. Significant fibrosis is defined as a METAVIR score of F2 or greater.

    Fibrosis Staging and Testing Terms

    F0
    METAVIR stageF0
    DefinitionNo fibrosis
    Scoring systemMETAVIR scoring system
    F1
    METAVIR stageF1
    DefinitionPortal fibrosis without septa
    Scoring systemMETAVIR scoring system
    Testing within 6 months of a liver biopsy is not medically necessary and will not be approved
    • Frequency limit: no more than once every 6 months.
    • Recent liver biopsy: testing within 6 months of the biopsy is not medically necessary.
    Denial Risk

    No Evidence of Chronic Liver Disease

    Document radiographic or serologic evidence of chronic liver disease before requesting liver fibrosis testing. Testing is not appropriate when there is no such evidence and will be denied.

    • Acceptable supporting evidence may include right upper quadrant ultrasound, CT, or MRI showing fatty liver or nodular liver.
    • Serologic or genetic support may include positive HFE gene testing for hereditary hemochromatosis.
    Denial Risk

    Excluded Tests and Indications

    Do not request coverage for liver fibrosis tests or indications that are excluded under this policy. These services are not covered because supporting evidence is insufficient or the indication falls outside the policy criteria.

    • Enhanced Liver Fibrosis Test is not covered.
    • All serologic testing not specifically listed as covered is not covered.
    • MRE is not covered for indications other than NAFLD.
    F2
    METAVIR stageF2
    DefinitionFew septa
    Scoring systemMETAVIR scoring system
    F3
    METAVIR stageF3
    DefinitionNumerous septa without cirrhosis
    Scoring systemMETAVIR scoring system
    F4
    METAVIR stageF4
    DefinitionCirrhosis
    Scoring systemMETAVIR scoring system
    Significant Fibrosis
    DefinitionA METAVIR fibrosis score of F2 or greater
    Minimum stageF2
    Scoring systemMETAVIR scoring system
    Non-Invasive Liver Fibrosis Testing
    DefinitionNon-invasive liver fibrosis tests consist of serologic tests and imaging tests
    Test categorySerologic tests
    Test categoryImaging tests